KRYSTAL -7
01 May 2023
KRYSTAL -7
NCT04613596
Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients KRAS G12C Mutation KRYSTAL-7
Mirati Therapeutics Inc.
Cancer Type | Lung |
---|---|
Trial Type | Treatment |
Phase | Phase II & Phase III |
Age Range | 18 years and older |
Sex | All |
Tumour Stream | - |
Cancer Stage | - |
Anticipated Start Date | 2020-12-02 |
Anticipated End Date | 2029-03-31 |
Hospital | Flinders Medical Centre |
---|---|
Clinical Trial Coordinator | Alison Richards |
Alison.Richards@sa.gov.au | |
Phone | 08 8206 4835 |
Principal Investigator | Chris Karapetis |
Recruitment Status | Recruiting |
Keep up to date with the latest news and breakthroughs